Exchange: NASDAQ·Updated 06:31 PM EST

About GRI

About

GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

Official Representatives

Sector:
Health Technology
Industry:
Biotechnology
Employees:
4

Frequently Asked Questions

Advertisement|Remove ads.